BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024)
BioLineRx (BLRX) recorded quarterly Current Deferred Revenue of $2.3 million in Q3 2024, down 58.83% quarter-over-quarter from $5.5 million in Q2 2024.
BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024) Analysis & Trends
BioLineRx's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $2.3 million for Q3 2024.
- In Q3 2024, Current Deferred Revenue changed N/A year-over-year to $2.3 million; the TTM figure through Sep 2024 stood at $2.3 million (changed N/A YoY), while the FY2023 annual figure was $13.0 million, changed N/A from the prior year.
- Current Deferred Revenue was $2.3 million for Q3 2024 at BioLineRx, down from $5.5 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $13.0 million in Q4 2023 to a low of $2.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 5.48 Mn |
| Mar 31, 2024 | 9.03 Mn |
| Dec 31, 2023 | 12.96 Mn |